F2R and myeloproliferative neoplasm: However, Ruxolitinib, which did not reveal and significant effect on PAR1 expression between MPN to healthy volunteers (Fig. 4A, B and D) was inhibited PAR1 expression significantly in the presence of a vorapaxar (p:0.0008) (Fig. 4F).